Although PD-L1 expression is used as a predictive marker for the response to blocking therapy [136], the variable effects of GCs on the PD-1/PD-L1 pathway may produce different outcomes, depending on the type of tumor that is targeted by therapy. Here, CD274 is linked to neoplasm.